Format

Send to

Choose Destination
JAMA Oncol. 2015 Dec;1(9):1340-1. doi: 10.1001/jamaoncol.2015.2274.

Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy.

Author information

1
Cutaneous Biology Research Center, Massachusetts General Hospital, Boston.
2
Cutaneous Biology Research Center, Massachusetts General Hospital, Boston2Department of Dermatology, Massachusetts General Hospital, Boston3Massachusetts General Hospital Cancer Center, Boston.
3
Massachusetts General Hospital Cancer Center, Boston.
PMID:
26270186
PMCID:
PMC4679487
DOI:
10.1001/jamaoncol.2015.2274
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center